259 related articles for article (PubMed ID: 7829789)
1. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
Faxon DP
J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
[TBL] [Abstract][Full Text] [Related]
2. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
[TBL] [Abstract][Full Text] [Related]
3. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
Berger PB; Holmes DR; Ohman EM; O'Hanesian MA; Murphy JG; Schwartz RS; Serruys PW; Faxon DP
J Am Coll Cardiol; 1996 Jan; 27(1):1-7. PubMed ID: 8522681
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR; Rensing BJ; Foley DP; Deckers JW; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
J Am Coll Cardiol; 1992 Oct; 20(4):767-80. PubMed ID: 1388181
[TBL] [Abstract][Full Text] [Related]
5. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
[TBL] [Abstract][Full Text] [Related]
6. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR; Foley DP; Rensing BJ; Serruys PW
Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
Desmet W; Vrolix M; De Scheerder I; Van Lierde J; Willems JL; Piessens J
Circulation; 1994 Jan; 89(1):385-92. PubMed ID: 8281674
[TBL] [Abstract][Full Text] [Related]
8. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
Brack MJ; Ray S; Chauhan A; Fox J; Hubner PJ; Schofield P; Harley A; Gershlick AH
J Am Coll Cardiol; 1995 Oct; 26(4):947-54. PubMed ID: 7560622
[TBL] [Abstract][Full Text] [Related]
9. Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty.
Yamabe T; Imazu M; Yamamoto H; Ueda H; Hattori Y; Hayashi Y; Sekiguchi Y; Ito M; Yamakido M
Coron Artery Dis; 1995 Jul; 6(7):573-9. PubMed ID: 7582196
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
[TBL] [Abstract][Full Text] [Related]
11. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
[TBL] [Abstract][Full Text] [Related]
12. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).
Serruys PW; Rutsch W; Heyndrickx GR; Danchin N; Mast EG; Wijns W; Rensing BJ; Vos J; Stibbe J
Circulation; 1991 Oct; 84(4):1568-80. PubMed ID: 1833088
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
[TBL] [Abstract][Full Text] [Related]
14. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitor in a human model of restenosis. MERCATOR ("Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis") Study Group.
Heyndrickx GR
Basic Res Cardiol; 1993; 88 Suppl 1():169-82. PubMed ID: 8357332
[No Abstract] [Full Text] [Related]
16. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Gibson CM; Goel M; Cohen DJ; Piana RN; Deckelbaum LI; Harris KE; King SB
J Am Coll Cardiol; 1998 Jul; 32(1):28-34. PubMed ID: 9669245
[TBL] [Abstract][Full Text] [Related]
17. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
[TBL] [Abstract][Full Text] [Related]
19. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.
Hoberg E; Dietz R; Frees U; Katus HA; Rauch B; Schömig A; Schuler G; Schwarz F; Tillmanns H; Niebauer J
Br Heart J; 1994 Mar; 71(3):254-60. PubMed ID: 8142195
[TBL] [Abstract][Full Text] [Related]
20. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II).
Savage MP; Goldberg S; Bove AA; Deutsch E; Vetrovec G; Macdonald RG; Bass T; Margolis JR; Whitworth HB; Taussig A
Circulation; 1995 Dec; 92(11):3194-200. PubMed ID: 7586303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
